A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Clinical Trial Grant
Awarded By
Takeda Development Center Americas, Inc
Start Date
November 18, 2024
End Date
September 11, 2029
Awarded By
Takeda Development Center Americas, Inc
Start Date
November 18, 2024
End Date
September 11, 2029